Paragon Bioservices, Inc.
w: http://www.paragonbioservices.com/
e: machacon@paragonbioservices.com
v: 410.975.4050
Paragon Bioservices, Inc. provides contract services for accelerating the development and manufacturing of biologics. Highly-flexible and responsive, we work in partnership with our clients to ensure efficient and cost-effective preclinical target validation services, process development and scale-up production of biopharmaceuticals for research purposes or Phase I/II clinical trials.
By accelerating the timeline from the bench to the clinic, Paragon’s integrated capabilities – spanning research, preclinical development and GMP manufacturing of biologics – result in continued renewal of intellectual property and increased return on investment for its clients.
Dr. Marco A. Chacón – Founder, CEO & President
With 30 years of research laboratory experience and 19 years of executive experience, Dr. Chacon has the depth of experience, energy and personal commitment to transform biotech startups into commercially-viable enterprises. He also founded Irazu Biodiscovery in 2000 based on his research and scientific insights regarding the mechanism of calorie-restriction protection. Dr. Chacon holds a Ph.D. in Nutritional Sciences from the University of Maryland.
Bob Eberwein – VP, GMP Manufacturing
Bob Eberwein joined Paragon in 2007 and brings over 25 years of biopharmaceutical manufacturing experience and knowledge to Paragon. Prior to joining Paragon, Mr. Eberwein spent eight years as the head of GMP manufacturing at Cambrex, producing a variety of bulk biologics for use in Phase I through Phase III clinical trials as well as commercial launch.
